septerna - Search News

News

Novo Nordisk Inks $2.2B Deal With Septerna

The Wall Street Journal on MSN · 13h

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Contract Pharma · 4h

Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic diseases.

Bloomberg on MSN · 1d

Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion.The two companies will start with four development programs that use different ways to potentially treat obesity,

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

1d

Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results